<ARTICLE> 5 <LEGEND> This schedule contains summary financial information extracted from the BioCryst Pharmaceuticals, Inc. Financial Statements, and is qualified in its entirety by reference to such financial statements. </LEGEND> <PERIOD-TYPE> 6-MOS <FISCAL-YEAR-END> DEC-31-1999 <PERIOD-END> JUN-30-1999 <CASH> 5,335,967 <SECURITIES> 18,980,886 <RECEIVABLES> 0 <ALLOWANCES> 0 <INVENTORY> 0 <CURRENT-ASSETS> 18,167,183 <PP&E> 3,476,033 <DEPRECIATION> 1,963,008 <TOTAL-ASSETS> 26,545,685 <CURRENT-LIABILITIES> 1,032,175 <BONDS> 0 <PREFERRED-MANDATORY> 0 <PREFERRED> 0 <COMMON> 149,876 <OTHER-SE> 25,048,930 <TOTAL-LIABILITY-AND-EQUITY> 26,545,685 <SALES> 0 <TOTAL-REVENUES> 3,040,597 <CGS> 0 <TOTAL-COSTS> 5,688,837 <OTHER-EXPENSES> 0 <LOSS-PROVISION> 0 <INTEREST-EXPENSE> 2,777 <INCOME-PRETAX> (2,651,017) <INCOME-TAX> 0 <INCOME-CONTINUING> 0 <DISCONTINUED> 0 <EXTRAORDINARY> 0 <CHANGES> 0 <NET-INCOME> (2,651,017) <EPS-BASIC> (.18) <EPS-DILUTED> (.18)